Friedreich (original) (raw)
Latest News for: friedreich
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
Nasdaq Globe Newswire 15 Jun 2026
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design� ... .
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia (Lexeo Therapeutics Inc)
Public Technologies 15 Jun 2026
Measures of neurologic and cardiac outcomes and relevant biomarkers, including modified Friedreich Ataxia Rating Scale (mFARS), Kansas City Cardiomyopathy Questionnaire (KCCQ), high-sensitivity (hs) troponin-I, and lateral wall thickness.
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia (Form 8-K) (Lexeo Therapeutics Inc)
Public Technologies 15 Jun 2026
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia ... Chief Executive Officer of the Friedreich's Ataxia Research Alliance (FARA).
Martin wants quick decision on Friedreich's Ataxia drug
RTE 09 Jun 2026
Taoiseach Micheál Martin has said he wants to see patients living with Friedreich's Ataxia in Ireland have access to the first treatment for the condition "as fast as we possibly can".
New Progress Toward Public Reimbursement of SKYCLARYS™ for People Living with Friedreich Ataxia in Quebec
Canada Newswire 08 Jun 2026
This outcome represents a positive step toward public reimbursement in the province for the only approved treatment in Canada for Friedreich ataxia ... Friedreich Ataxia ... https.//www.ninds.nih.gov/health-information/disorders/friedreich-ataxia.
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia (Design Therapeutics Inc)
Public Technologies 18 May 2026
After four weeks of DT-216P2 treatment at the 1 mpk dose cohort, patients demonstrated mean improvements from baseline of 6.4 points in the modified Friedreich's Ataxia Rating Scale (mFARS) and 2.7 points in the Upright Stability Score.
- 1
Article Search
tools
You can search using any combination of the items listed below.
Language:
Sort:
Indexed:
Search:
Duplicates: